In contrast, drugs modeled after gastrointestinal hormones, such as glucagon-like peptide-1 (GLP-1), have been shown to exhibit fewer side effects while demonstrating high efficacy in obesity treatment. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.